Sanofi SA (SAN) Given a €83.00 Price Target by S&P Global Analysts
Sanofi SA (EPA:SAN) has been given a €83.00 ($97.65) price objective by analysts at S&P Global in a note issued to investors on Friday. The firm presently has a “neutral” rating on the stock. S&P Global’s price target indicates a potential upside of 5.04% from the stock’s previous close.
Several other brokerages have also recently issued reports on SAN. HSBC Holdings plc set a €81.00 ($95.29) target price on shares of Sanofi SA and gave the stock a “neutral” rating in a report on Wednesday, August 30th. Jefferies Group LLC set a €87.00 ($102.35) target price on shares of Sanofi SA and gave the stock a “neutral” rating in a report on Thursday, August 24th. Deutsche Bank AG set a €96.00 ($112.94) target price on shares of Sanofi SA and gave the stock a “buy” rating in a report on Tuesday, August 1st. J P Morgan Chase & Co restated a “neutral” rating and issued a target price on shares of Sanofi SA in a report on Thursday. Finally, Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) target price on shares of Sanofi SA and gave the stock a “neutral” rating in a report on Monday, August 7th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of €87.24 ($102.63).
Shares of Sanofi SA (EPA:SAN) opened at €79.02 ($92.96) on Friday. Sanofi SA has a 1 year low of €70.94 ($83.46) and a 1 year high of €92.97 ($109.38).
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/sanofi-sa-san-given-a-83-00-price-target-by-sp-global-analysts/1679532.html.
Sanofi SA Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with Analyst Ratings Network's FREE daily email newsletter.